Poland is slowly expanding beyond its position as a central European generics hub. More established companies are adding innovative medicine pipelines and a small number of biotechs are making international deals.

The proceeds from the impressive series B financing will help progress roginolisib through Phase II trials.

The merger of Freeline and SwanBio is establishing an entity with secure financing to advance their respective gene therapies for Gaucher’s disease and adrenomyeloneuropathy.

And the deals it has signed recently will not begin to pay off for some years to come.